实体肿瘤治疗疗效评估系统的发展及其在肝癌靶向治疗中的应用现状  

Development of efficacy evaluation system for solid tumors and its application status in targeted therapy of liver cancer

作　　者：林康强 喻亚群[1] LIN Kangqiang;YU Yaqun(Department of Hepatopancreatobiliary Surgery,Affiliated Hospital of Guilin Medical University,Guilin,Guangxi 541001,China)

机构地区：[1]桂林医学院附属医院肝胆胰外科,广西桂林541001

出　　处：《中国普通外科杂志》2022年第7期958-965,共8页China Journal of General Surgery

基　　金：广西自然科学基金资助项目(2018GXNSFDA281003,2017GXNSFAA198039,2022GXNSFAA035509);广西肝脏损伤与修复分子医学重点实验室基金资助项目(GXLIRMMKL-K202009)。

摘　　要：由于靶向治疗、免疫治疗的发展兴起,实体肿瘤的治疗已进入精准医学时代。因此,目前提出了多种以传统实体瘤疗效评估系统为基础的,与靶向治疗、免疫治疗相适应的新实体瘤疗效评估标准。笔者就实体肿瘤治疗疗效评价系统的发展与现状,特别是肝癌靶向治疗疗效评估方面进行系统综述,以期为临床实践提供参考。With the development of targeted therapy and immunotherapy,the treatment of solid tumors has entered the era of precision medicine.As a result,several new response evaluation criteria systems for solid tumors,which are based on the traditional evaluation systems in solid tumors and comply with the requirements of targeted therapy and immunotherapy,have been developed.Here,the authors systemically present the development and current status of response evaluation systems for solid tumors,emphatically from the aspect of targeted therapy of liver cancer,hoping to provide a guidance for clinical practice.

关 键 词：实体肿瘤疗效评价标准 肝肿瘤 分子靶向治疗 综述 

分 类 号：R730.5[医药卫生—肿瘤]